Phase 3 Trial Launches to Assess EGFR Inhibitor for NSCLC Subset
August 4th 2023Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.
First U.S. Patient Treated in Study of Novel Drug-Chemo Combo for NSCLC Subset
May 23rd 2023Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.
Phase 3 Trial of Fablyn Plus Verzenio for Metastatic Breast Cancer Initiates Registration
March 20th 2023Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.
First Patients Dosed With Novel Inhibitor in Trial on Relapsed or Refractory AML Subset
February 11th 2023Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.